Maximum Duration of Cangrelor Infusion Before CABG
Cangrelor can be administered continuously for at least 48 hours before CABG, and potentially up to 7 days based on clinical trial data, with the infusion discontinued 1-6 hours prior to surgery. 1, 2
FDA-Approved Dosing and Duration
The FDA label for cangrelor specifies that the standard dosing is a 30 mcg/kg IV bolus followed by 4 mcg/kg/min infusion for at least 2 hours or the duration of PCI, whichever is longer 1. However, this represents the typical PCI indication, not the bridging indication before CABG.
Bridging to CABG: Extended Duration Protocol
For patients requiring CABG who need antiplatelet bridging, the evidence supports much longer infusion durations:
The BRIDGE trial (the highest quality study specifically addressing this question) administered cangrelor at a lower "bridge" dose of 0.75 mcg/kg/min (compared to the standard 4 mcg/kg/min PCI dose) for at least 48 hours, with the infusion discontinued 1-6 hours before CABG surgery 2
This bridging strategy maintained platelet inhibition (98.8% of patients maintained PRU <240) without increasing excessive CABG-related bleeding (11.8% vs 10.4% in placebo) 2
Real-World Practice Patterns
Recent registry data demonstrates variable duration in clinical practice:
The CAMEO registry showed that among CABG patients, 26% received "bridge" dosing (≤1 mcg/kg/min) and the median time from admission to CABG was 3.8 days in cangrelor-treated patients 3
Cangrelor has been used for extended periods in critically ill patients unable to take oral medications, though specific maximum durations beyond 7 days lack robust safety data 4, 5
Practical Algorithm for Duration
For patients awaiting CABG:
- Discontinue oral P2Y12 inhibitor when CABG is planned
- Initiate cangrelor at bridge dose (0.75 mcg/kg/min) within hours of stopping oral agent
- Continue infusion for the entire waiting period (typically 2-7 days)
- Stop cangrelor 1-6 hours before surgery to allow platelet function recovery 2
Maximum practical duration: While the BRIDGE trial used "at least 48 hours," there is no defined upper limit in the literature. Infusions have been safely continued for up to 7 days based on the typical waiting period after stopping ticagrelor or clopidogrel before CABG 6, 2, 3.
Critical Dosing Distinction
Two different cangrelor dosing strategies exist:
- PCI dose: 4 mcg/kg/min (standard FDA-approved dose) 1
- Bridge dose: 0.75 mcg/kg/min (used in BRIDGE trial for pre-CABG bridging) 2
The lower bridge dose is appropriate for extended pre-operative use, while the higher PCI dose is intended for acute procedural antiplatelet therapy lasting only 2-4 hours.
Safety Considerations
- Bleeding risk: The BRIDGE trial showed no significant increase in excessive CABG-related bleeding with cangrelor bridging 2
- High-risk populations: Patients on ECMO or in cardiogenic shock have substantially higher bleeding rates (up to 100% in ECMO patients in one series), requiring careful risk-benefit assessment 4
- Reconstituted stability: Diluted cangrelor is stable for 24 hours in normal saline and 12 hours in 5% dextrose at room temperature 1
Transition After CABG
Post-operatively, resume oral P2Y12 inhibitor when hemostasis is adequate and platelet count >50,000/µL 6. Ticagrelor 180 mg can be given during or immediately after cangrelor discontinuation, while clopidogrel 600 mg or prasugrel 60 mg should be given immediately after stopping cangrelor 1.